12th Market Access, Pricing & Reimbursement Global Congress 2025 Europe

Comprehensive Strategies and Embracing Innovations to Overcome Barriers in Patient Access

  • 00Days
  • 00Hours
  • 00Minutes
  • 00Seconds

Market Access, Pricing & Reimbursement

Dear Colleagues,

Market access is the process of ensuring that patients have access to effective medicines and
medical technologies if and when they need them. Market access is a critical part of pharmaceutical strategies, and it’s important to remove any obstacles that prevent patients from receiving treatments. It is a crucial phase in a product’s lifecycle that can determine its commercial success.

The pharmaceutical market is expected to grow in the years to come regardless of a recent slowdown in key markets across the globe. The increase is exacerbated by the growing and ageing population in key markets. Aside from this, increasing access to Pharmaceuticals to poor and middle-class families due to increases in disposable income also drives the industry’s growth. Pharma companies focusing on Rare and speciality medicines is another aspect leading the growth. Innovations attracting investments even from non-pharma companies are also sustaining the growth in the pharmaceutical industry.

The pharmaceutical industry is one of the major players in the healthcare sector. Payers want to provide access and fund innovative treatments to improve patient care but governments across Europe are struggling to balance the desire to provide timely access to innovative medicines with the need to contain healthcare spending due to the increasing pressure between the demands of the EU, national governments and regional authorities.

As healthcare budgets are continuously rising in Europe, governments implement a wide variety of policies to control them with the help of different public regulatory bodies that are involved in pharmaceutical coverage decisions across Europe. International collaboration among HTA and regulatory bodies can promote knowledge exchange, as do the actions payers take in an effort to reduce costs while maintaining quality care.

The upcoming 2025, Market Access, Pricing and Reimbursement Global Congress Europe will present a dynamic approach to key trends and insights on market access, health
technology assessment, real-world data, patient access, pricing and reimbursement on the current European landscape.

This year, we are putting together an agenda that addresses “Comprehensive Strategies and Embracing Innovations to Overcome Barriers in Patient Access”. We are gathering together high calibre expert speakers to participate and share their knowledge and expertise through Keynote Presentations and Panel discussions, addressing all aspects of the industry.

We look forward to welcoming you to the MAPR 2025 congress!

Sincerely yours,  

Jocelyn Raguindin
Jocelyn Raguindin

Jocelyn is Conference Director at Facilitate Live. She has over 15+ years experience in organizing pharma-industry conferences and has been at the helm of every PGE conference since 2013. Jocelyn is based in London, UK.

Why you should attend:

GAIN THE LATEST INSIGHTS ON:

You Will Meet:

WHO SHOULD ATTEND: 

Network with members of boards, VP’s, Directors, Heads/Chiefs and Senior Managers of leading biopharmaceutical and biotech companies, government, CRO and solution providers involved in:

0 +
speakers
0
days Congress
0 +
Presentation
0 +
Attendees

Key Industry Expert 2024 Speakers

(Full 2025 Speakers line-up available shortly)

Professor James LEVINE MD PhD

President

Fondation Ipsen

MARTA CONTENTE

Sr Director, Pipeline Head of Immunology

GHEVO, TEVA

ROBERT MITCHELL-THAIN

CEO

PBC Foundation

ESTHER NZENZA

Founder and CEO

Decisive Consulting Ltd.

RIAD DIRANI

VP, Global HEOR, Medical Operations & Excellence

Teva

Alison Lawrence

Associate Principal

Decisive Consulting Ltd

LINDSAY BIRRELL

Co- CEO, Realise Advocacy, Chair of trustees

Medics 4 Rare Diseases

JOSIE GODFREY

Co-Founder and CEO, Realise Advocacy, Director

JG Zebra Consulting

Zavy Gabriel

Head of International Market Access

AstraZeneca

Vasiliki Patsioura

Global Pricing Implementation Lead

AstraZeneca

David Alderson

Director

Cogentia

RYOTARO ISHIKAWA

Global Market Access Director

Novartis

FABIAN SCHMIDT

Global Head, Market Access, HEOR & Policy

Recordati Rare Diseases

MATTHIAS HECK

Attorney-at-law, Senior Director, International TA Policy Strategy

Alexion AstraZeneca Rare Disease

NICKI K CATTERICK

Vice President, Global Value and Access Oncology

IPSEN

MATIAS OLSEN

Senior Manager, Public Affairs & Policy

EUCOPE

Hazel Dawson

Market Access Director UK & Ireland

Alexion Pharma UK

Sandeep Kiri

Global Head of Health Economics and HTA Evidence

UCB

STEFANO ROMANELLI

Senior Government Affairs

EUCOPE

Janek Hendrich

Value Strategies Lead - Oncology

AstraZeneca

Kirsty Hoyle

CEO

Metabolic Support UK

EIRINI PALAKA

AccesVice President, Global Value & Access, Rare Diseases Policy

IPSEN

Shaun Rowark

Associate Director for Data Access and Analysis,

NICE

Francis Pang

SVP Global Market Access and Geographic Expansion

Orchard Therapeutics

Chris Grimes-Crompton

Principal Consultant

Decisive Consulting Ltd

Richard Macaulay

SVP, Global Pricing and Market Access

PRECISIONadvisors

Maarten Van Baelen

Executive Director

Plasma Protein Therapeutics Association

ALEXANDER BASTIAN

VP, Value & Market Access

AM-Pharma

Schedule

Content Rich Program Agenda!  Featuring Keynote Presentations, Stream Sessions, Panel, and Round Table Discussions.

Robert Mitchell-Thain, CEO, PBC Foundation

MARKET ACCESS TRENDS & STRATEGIES

  • Addressing varying market access and payer models to accelerate patient access to treatment
  • How can manufacturers enhance their negotiation tactics with payers
  • How to secure favourable positioning on drug formularies and national guidelines
  • Value-based contracting including alternative payment models
  • Tackling the challenges on drug affordability
  • Creating a robust clinical evidence for HTA assessment
  • Future outlook

Moderator:

Panelist:

  • Impact of recent changes on companies that decide to invest in the EU, with consequences that will also affect market access in Member States, patients, healthcare systems and EU competitiveness.
  • Recommendations on how to ensure efficient and effective implementation of the JCA at the national level
  • Identify metrics that will enable iterative learning among stakeholders.
  • Future considerations for involvement in JCA and national implementation at the Member State level.
  • The need for better access to quality data
  • Expanding clinical research
  • Scaling up manufacturing of advance therapies
  • Creating spending decisions that aligns with healthcare priorities
  • Building a globally competitive ecosystem
  • When and how to integrate value planning into development
  • Staying responsive to changing market conditions
  • Trends to watch
  • Enabling diverse perspectives through timely engagement
  • Addressing the factors that made the launch environment more challenging
  • Capabilities needed for an effective drug launch
  • How to best leverage outsourced partners to achieve success.
  • Best practices to achieve successful commercialisation
  • Trends in oncology launches in Europe over the past three years reveal a trend for immature data packages and significant challenges when it comes to clinical benefit assessments and pricing negotiations
  • Analysis of recent HTAs highlight significant challenges in demonstrating overall survival benefit remain, given the highly complex and increasingly personalised nature of oncology treatment paradigms
  • What strategies are manufacturers pursuing in order to overcome such challenges? Are pharma stakeholders opting for lower-risk / lower-return strategies?
  • Why and how enterprises should invest into early HEOR and pathway improvement?
  • How AI can impact early HEOR and pathway improvement evaluations: key benefits to the life sciences and medtech industry
  • Case examples from the UK
  • Challenges and obstacles in bringing this highly complex therapies to market
  • Lessons learned and applications for new entrants
  • Strategies that can be taken to improve timely market access and access for patients
  • Innovative contracting for cell & gene therapies in the EU
  • Stakeholder collaboration on the road towards a solution
  • Understanding and including the patients’ perspectives in designing clinical trials and clinical endpoint
  • Key principles that ensure access to treatment based on need
  • Patient-centeredness, patient advocacy
  • New landscape for risk-sharing agreements among manufacturer, payer and patients
  • Understand the benefits of a good collaboration between payers and pharma companies to ensure patient access
  • What do the decision-makers on drug usage think today about how the industry is responding to the immense challenges it is facing?
  • Navigating complex requirements to achieve and maintain market access in the EU and around the world
  • Integrating evidence development with market access strategy
  • Practical approaches and strategic planning
  • Best practices
  • Access to innovative medicines remains a key issue worldwide
  • Identifying the root cause of inequitable access
  • Limitations of the some of the initiatives to address this such as the EUnetHTA JCA and the changes in legislation in Europe
  • Developing solutions that are sustainable and scalable
  • How can pharmaceutical companies and health authorities work together to bridge the gap

Josie Godfrey, Co-Founder and CEO, Realise Advocacy

PRICING & REIMBURSEMENT

  • Challenges in drug pricing and reimbursement
  • How to navigate a complex balance between financial and strategic risks
  • Strategies to offset regulatory and inflationary pressures.
  • Addressing environmental, social, and corporate governance issues
  • Encouraging cross-functional or cross-company collaborations
  • Advantages of market access teams in payer relationship
  • Payer evidence requirement in early development
  • Best practices to obtain better pricing and reimbursement
  • Strategies to improve a better payer relationship
  • Navigating the complex global pricing dynamics
  • Aligning global pricing with the company strategy
  • Setting prices and dealing with price changes in global markets
  • Effective communications with internal and external stakeholders
  • Importance of stakeholder collaboration
  • Understanding the benefits of a good collaboration between payers and pharma to ensure appropriate patient access
  • Keeping on top of pricing and market access trends
  • Identify a clinical or economic advantage and generate the appropriate clinical and health economic evidence to support a strong value proposition
  • Optimising the use of Patient-Reported Outcomes
  • Unlocking data from early access
  • Effective communications with internal and external stakeholders
  • Embracing the digital vision
  • Why is this important?
  • Current state of play
  • Barriers to Equity Pricing
  • Potential solutions and some principles to maximize impact of Equity Pricing
  • Objective: Activating the full stakeholder ecosystem to shift conversation from price to value to get access to innovative therapies
  • Why is the full stakeholder ecosystem important for gaining access in the future?
  • How to Identify the stakeholder ecosystem for access success
  • Step by step: Setting up a cross-functional program for access success
  • Exploring how early economic modelling as a foundational tool can be used to optimise value, from early to late development.
  • An exploration of the principles, and some case studies. 

David Alderson, Director, Cogentia

  • Assessment of financial benefit from tendering
  • Evaluating its impact on prices and market concentration
  • Consideration of its operational framework
  • Tendering for pharmaceuticals as a reimbursement tool
  • As innovation brings cancer drugs & curative medicines to the forefront of healthcare systems, how are payers affording to pay for this innovation ?
  • what are the new determinants of value in healthcare, and the geopolitical drivers for value based agreements & innovative contracting ?
  • If the drugs don’t work – I want my money back! – access into a global tracker of over 700 innovative contracts from around the globe
  • Who’s shifting the paradigm – adoption curves for those manufacturers leading the way in capabilities for innovative contracting

Moderator:

David Alderson, Director, Cogentia

Panellists:

  • The importance of making MA the core of the company
  • Bridge between pre-launch strategy and post-launch
  • Increasing collaboration between EU countries
  • Frontiers in Health Care
  • What will the future bring?

Moderator:

Panelists: 

2024 sponsors & Exhibitors

Newsletter Sign Up

No Spam - You will only receive relevant information on Market Access, Pricing & Reimbursement, and event updates

Testimonials

what people say

Thank you for a good experience with the PARADIGM Global Events… very high level, very good Organization, we overpassed our expectatives, we will be pending for another congress related to pharmaceutical and biotech… we learned a lot, and i think that the content of agenda was state of the art, thank you again.
Salvador Berrios
ERP/ CRM / Product Configurator Manager
The consistently high quality of international faculty was most impressive. It was also obvious that they were carefully chosen not only for their particular expertise but also for their ability to communicate the subject matter to clinical and non-clinical participants alike. As market access consultant for pharma clients of various sizes, I now feel much better prepared to explain the nuances & dynamics involved in bringing their products to market. In addition, I am in a much better position to intelligently advice my clients & help them set realistic expectations
Thomas Martin
Associate Vice President, VCGA - Quintiles
I was impressed with the organization of this event. I attend many conferences per year and find the organizers on site to be detached and not focus on good service to the delegates. This team was even providing weather forecast warning to ensure everyone was aware and made appropriate plans. Well Done.
Adriana E. Manzi
PhD, Managing Director, Atheln, Inc

Previous events

Book Your Place Now! 

Register To Attend Now!

Take Advantage of the Super Early Bird Discount. Group Discounts Also Available. 

Location

Scroll to Top